GLP-1受体激动剂可降低银屑病患者死亡、心血管及精神风险:大规模队列研究
该回顾性队列研究基于美国TriNetX数据库,纳入银屑病合并糖尿病或肥胖患者,经1:1倾向评分匹配后每组3048例,比较GLP-1RA与其他降糖/减重药物的结局。结果显示GLP-1RA治疗与全因死亡、主要心血管不良事件及酒精/物质滥用风险显著降低相关,且典型药物不良事件未增加,风险降低幅度在银屑病人群中比无银屑病人群更明显。
要点
- GLP-1RA治疗与银屑病患者全因死亡风险显著降低相关(HR 0.219)。
- 主要心血管不良事件风险亦显著降低(HR 0.561)。
- 酒精滥用和物质滥用风险分别降低(HR 0.346和0.510)。
核心结论
- GLP-1RA治疗在银屑病患者中安全,与心血管和精神共病风险及死亡率降低相关。
- 风险降低幅度在银屑病人群中显著高于无银屑病人群。
研究设计与样本
- 回顾性基于人群的队列研究,使用美国TriNetX数据库真实世界数据。
- 比较随访2年内因糖尿病或肥胖接受GLP-1RA治疗的银屑病患者与其他系统降糖或减重药物患者。
- 经1:1倾向评分匹配相关风险因素后,每组各纳入3048例参与者。
- 另在无银屑病队列中重复分析,并通过两项敏感性分析(更晚随访期或排除脓疱型银屑病患者)验证结果。
主要发现
- 匹配队列中,GLP-1RA组(女性60.4%,平均年龄56.94岁,SD 12.02)与其他药物组(女性61.9%,平均年龄56.42岁,SD 14.16)相比,全因死亡风险显著降低(HR 0.219,95%CI 0.123-0.391;P<0.001)。
- 主要心血管不良事件风险显著降低(HR 0.561,95%CI 0.442-0.714;P<0.001)。
- 酒精滥用风险降低(HR 0.346,95%CI 0.174-0.685;P=0.009)。
- 物质滥用风险降低(HR 0.510,95%CI 0.350-0.743;P=0.002)。
- GLP-1RA队列中典型药物不良事件未更频繁发生。
临床怎么用
- 对于银屑病合并肥胖或糖尿病的患者,医生应考虑使用GLP-1RA类药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis is associated with a significant comorbidity burden, especially cardiovascular and metabolic complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, used to treat obesity and diabetes, could potentially reduce comorbidities in patients with psoriasis. OBJECTIVES: To investigate all-cause mortality, cardiovascular, inflammatory and psychiatric outcomes, and adverse events in patients with psoriasis treated with GLP-1RAs. METHODS: This retrospective population-based cohort study used real-world data from the US TriNetX database. Patients with psoriasis who were treated for diabetes or obesity with a GLP-1RA during the follow-up period of 2 years were compared with those treated with other systemic antidiabetic or antiobesity drugs. After 1 : 1 propensity score matching for relevant risk factors, 3048 participants were included in each cohort. Primary outcomes included the risk of cardiometabolic, psychiatric and autoimmune sequelae of psoriasis, as well as all-cause mortality and potential adverse drug events. The analysis was repeated using cohorts without psoriasis and the results were further validated through two sensitivity analyses involving (i) later follow-up periods or (ii) the exclusion of patients with pustular psoriasis. RESULTS: In the matched cohorts of 3048 patients with psoriasis treated with a GLP-1RA [60.4% women, mean (SD) age 56.94 (12.02) years] vs. other antidiabetic and antiobesity drugs [61.9% women, mean (SD) age 56.42 (14.16) years], GLP-1RA treatment was associated with significantly decreased all-cause mortality [hazard ratio (HR) 0.219, 95% confidence interval (CI) 0.123-0.391; P < 0.001] and reduced risk of major adverse cardiac events (HR 0.561, 95% CI 0.442-0.714; P < 0.001). Additionally, lower risks for alcohol (HR 0.346, 95% CI 0.174-0.685; P = 0.009) and substance abuse (HR 0.510, 95% CI 0.350-0.743; P = 0.002) were found. Typical adverse drug events were not more frequent in the GLP-1RA cohort. The risk reductions were more pronounced in the cohorts with psoriasis than in those with obesity or diabetes without psoriasis. The findings were consistent across all sensitivity analyses. CONCLUSIONS: GLP-1RA treatment was safe and associated with reduced risks of cardiovascular and psychiatric comorbidities, as well as lower mortality in patients with psoriasis, with risk reductions markedly higher than in cohorts without psoriasis. Physicians should consider this drug class for patients with psoriasis and comorbid obesity or diabetes. Psoriasis is a common skin condition. It affects 2% to 3% of the world’s population. People with psoriasis can have a higher risk of heart diseases and mental health conditions like depression. A new class of drugs called ‘GLP-1RA’ is being used to treat people with obesity and type 2 diabetes. These drugs have been effective in reducing risks of heart disease and suicidal thoughts. We are researchers from Germany, Israel and Spain. We used data from the USA to investigate whether patients with psoriasis could benefit from GLP-1RA treatment. We analysed electronic records collected by healthcare providers in the USA. Patients with psoriasis were selected. We then identified who was treated with GLP-1RA or with other drugs for diabetes and obesity. Next, we looked at how many of these patients developed heart, mental health and autoimmune conditions. Afterwards, we performed the same analysis with patients without psoriasis. We found that patients with psoriasis treated with GLP-1RA had a lower risk of dying. They also had lower risks of heart disease and alcohol or drug abuse. However, the risk was no different for unwanted drug effects or other autoimmune diseases. The risk reductions were higher than in people without psoriasis. Our study findings suggest that people with psoriasis could benefit from GLP-1RA treatment for obesity or type 2 diabetes. This could help lead clinicians to provide more treatment choices for people with psoriasis.
引用
- Olbrich H, Kridin K, Zirpel H, et al. Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study. Br J Dermatol. 2026. PMID: 40897378. doi:10.1093/bjd/ljaf346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。